İlhan AFŞAR, Nükhet KURULTAY, Aslı Gamze ŞENER, Gül Süreyya YURTSEVER

İn vitro susceptibility of methicillin-resistant staphyloccoccus aureus to linezolid by E-test method

Metisiline dirençli Gram pozitif infeksiyonların insidasındaki artış devam etmekte ve linezolid hastalara yeni tedavi seçeneği sağlamaktadır. Çalışmanın amacı; klinik örneklerden soyutlanan metisiline dirençli Staphylococcus aureus (MRSA) suşlarının linezolide in-vitro duyarlılığını araştırmaktır. Toplam 88 MRSA suşunun linezolide in-vitro duyarlılığı E-test yöntemiyle araştırılmış, tüm suşlar duyarlı bulunmuştur (MİK

E-test yöntemiyle metisiline dirençli staphyloccoccus aureus suşlarının linezolide in-vitro duyarlılıği

The incidence of methicillin-resistant gram-positive infections continue to increase and linezolid may provide new options to treat patients. The aim of this study was to investigate the in vitro susceptibility of methicillin-resistant Staphylococcus aureus (MRSA) strains isolated from clinical specimens to linezolid. The in vitro susceptibility of a total of 88 MRSA isolates to linezolid was investigated by the E-test. All MRSA isolates were found to be susceptible to linezolid (Minimal inhibitory concentration < 4.0 mg/l). The results of the present study demonstrated that linezolid has a good in vitro activity against MRSA in Turkey. This drug could be a promising therapeutic option against MRSA.

PDF

___

1. Abb J: In vitro activity of linezolid, quinupristin/ dalfopristin, vancomycin, teicoplanin, moxifloxacin and mupirocin against methicillin-resistant Staphylococcus aureus: comparative evaluation by the E test and a broth microdilution method, Diagn Microbiol Infect Dis 2002;43(4):319-21.
2. Clinical and Laboratory Standards Institute: Performance Standards for Antimicrobial Susceptibility Testing: Sixteenth Informational Supplement, M100-S16, CLSI, Wayne, PA (2006).
3. Clinical and Laboratory Standards Institute: Performance Standards for Antimicrobial Susceptibility Testing: Seventeenth Informational Supplement, Document M100-S12, CLSI, Wayne, PA (2007).
4. Cuevas O, Cercenado E, Goyanes MJ et al: Staphylococcus spp. in Spain: present situation and evolution of antimicrobial resistance (1986-2006), Enferm Infect Microbiol Clin 2008;26(5):269-77.
5. Dizbay M, Sipahi AB, Günal Ö et al: Metisiline dirençli Staphylococcus aureus izolatlarında glikopeptid ve linezolid direncinin araştırılması, ANKEM Derg 2007;21(1):23-6.
6. Kaya O, Akcam FZ, Temel EN: In vitro activities of linezolid and tigecycline against methicillin-resistant Staphylococcus aureus strains, Microb Drug Resist 2008;14(2):151-3.
7. Micek ST: Alternatives to vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections, Clin Infect Dis 2007;45(Suppl 3):S184-90.
8. Mouton JW, Jansz AR: The DUEL study: a multicenter in vitro evaluation of linezolid compared with other antibiotics in the Netherlands, Clin Microbiol Infect 2001;7(9):486-91.
9. Simonsen GS, Bergh K, Bevanger L et al: Susceptibity to quinupristin-dalfopristin and linezolid in 839 clinical isolates of gram-positive cocci from Norway, Scand J Infect Dis 2004;36(4):254-8.
10. Tunger A, Aydemir S, Uluer S, Çilli F: In vitro activity of linezolid and quinupristin/dalfopristin against gram-positive cocci, Indian J Med Res 2004;120(6):546-52.
11. Velissariou IM: Linezolid in children: recent patents and advances, Recent Pat Antiinfect Drug Discov 2007;2(1):73-7.
12. Zhanel GG, DeCorby M, Nichol KA et al: Antimicrobial susceptibility of 3931 organisms isolated from intensive care units in Canada: Canadian National Intensive Care Unit Study, 2005/2006, Diagn Microbiol Infect Dis 2008;62(1):67-80.